FourThought Financial LLC Has $948,000 Position in Progyny, Inc. (NASDAQ:PGNY)

FourThought Financial LLC increased its position in Progyny, Inc. (NASDAQ:PGNY – Get Rating) by 30.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 25,586 shares of the company’s stock after buying an additional 5,944 shares during the period. FourThought Financial LLC’s holdings in Progyny were worth $948,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Raymond James & Associates grew its holdings in Progyny by 27.2% during the first quarter. Raymond James & Associates now owns 72,220 shares of the company’s stock valued at $3,712,000 after purchasing an additional 15,432 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Progyny by 1.4% during the first quarter. Bank of New York Mellon Corp now owns 672,710 shares of the company’s stock valued at $34,579,000 after purchasing an additional 9,017 shares during the last quarter. US Bancorp DE grew its holdings in Progyny by 92.3% during the first quarter. US Bancorp DE now owns 14,276 shares of the company’s stock valued at $734,000 after purchasing an additional 6,854 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in Progyny by 22.6% during the first quarter. PNC Financial Services Group Inc. now owns 12,296 shares of the company’s stock valued at $632,000 after purchasing an additional 2,265 shares during the last quarter. Finally, Natixis Advisors L.P. grew its holdings in Progyny by 47.3% during the first quarter. Natixis Advisors L.P. now owns 29,595 shares of the company’s stock valued at $1,521,000 after purchasing an additional 9,497 shares during the last quarter. Institutional investors and hedge funds own 86.12% of the company’s stock.

Wall Street Analysts Forecast Growth

PGNY has been the topic of several analyst reports. KeyCorp lowered their price target on Progyny from $55.00 to $45.00 and set an “overweight” rating on the stock in a report on Monday, December 19th. JPMorgan Chase & Co. lowered their price target on Progyny from $78.00 to $62.00 and set an “overweight” rating on the stock in a report on Friday, November 18th. Finally, SVB Leerink reissued a “market perform” rating and issued a $34.00 price objective (down from $59.00) on shares of Progyny in a research report on Thursday, January 5th. One analyst has rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $49.25.

Insider Buying and Selling

In related news, Director Norman Payson sold 6,617 shares of the firm’s stock in a transaction on Wednesday, December 21st. The stock was sold at an average price of $31.65, for a total value of $209,428.05. Following the completion of the transaction, the director now directly owns 279,063 shares of the company’s stock, valued at $8,832,343.95. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, Director Norman Payson sold 6,617 shares of the firm’s stock in a transaction on Wednesday, December 21st. The stock was sold at an average price of $31.65, for a total value of $209,428.05. Following the completion of the transaction, the director now directly owns 279,063 shares of the company’s stock, valued at $8,832,343.95. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Chairman David J. Schlanger sold 1,285 shares of Progyny stock in a transaction on Tuesday, January 31st. The shares were sold at an average price of $35.00, for a total value of $44,975.00. Following the transaction, the chairman now directly owns 74,716 shares of the company’s stock, valued at $2,615,060. The disclosure for this sale can be found here. Insiders sold a total of 222,433 shares of company stock valued at $7,945,078 over the last ninety days. 14.00% of the stock is owned by company insiders.

Progyny Trading Up 2.3 %

PGNY opened at $33.86 on Thursday. Progyny, Inc. has a 1-year low of $25.67 and a 1-year high of $53.10. The stock has a market capitalization of $3.16 billion, a price-to-earnings ratio of 110.03 and a beta of 1.56. The business has a 50 day moving average of $33.11 and a 200-day moving average of $35.58.

Progyny (NASDAQ:PGNY – Get Rating) last posted its quarterly earnings data on Monday, February 27th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.01. The company had revenue of $214.32 million during the quarter, compared to analysts’ expectations of $211.78 million. Progyny had a return on equity of 9.24% and a net margin of 3.86%. Progyny’s revenue for the quarter was up 68.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.15 earnings per share. Equities analysts predict that Progyny, Inc. will post 0.27 EPS for the current year.

About Progyny

(Get Rating)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.